PACTR201901862142418已完成2 期
Randomized Phase II Study Comparing the Standard Protocol of Gemcitabine with Low Dose Gemcitabine over 6 Hours in Patients with Advanced Pancreatic Adenocarcinoma
South Egypt cancer Institute0 个研究点目标入组 100 人开始时间: 2019年1月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Patients with advanced pancreatic cancer in males or females with age of 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, chemotherapy-naïve, and adequate hematologic, hepatic, and renal functions.
排除标准
- •1.Patient refuses to be enrolled in study.
- •2.Contraindication to gemcitabine
- •3.Concurrent anticancer or radiation therapy.
- •?Start of study therapy must be at 4 weeks after completion of previous anticancer therapy and 2 weeks from the date of last radiation.
- •4.Use of gemcitabine within the past 3 months with progression.
- •5.Any psychiatric illness/social situations that would limit compliance with study requirements.
- •6.Pregnant or nursing women.
- •7.Synchronous malignancies i.e associated other body cancers.
研究者
相似试验
尚未招募
2 期
A clinical trial comparing pulmonary complications in two routes of gastric conduit placement after esophagectomyCTRI/2024/02/062245AIIMS NEW DELHI
已完成
2 期
A phase II randomized controlled trial comparing perioperative mFOLFOXIRI with perioperative chemoradiotherapy for locally advanced rectal cancer.Rectal cancerJPRN-UMIN000018624Osaka Medical College Hospital34
已完成
2 期
Oral drug therapy as palliative chemotherapy in Head and Neck cancersCTRI/2014/07/004791Tata Memorial Hospital110
进行中（未招募）
不适用
Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom - Topotecan wöchentlich vs. Topotecan Tag 1-5 bei platinresistentem OvarialkarzinomPatientinnen mit Ovarialkarzinom und Rezidiv / Progress < 6 Monate nach Ende der Primärtherapie mit Platin und TaxanEUCTR2005-001559-39-DECharité-Campus Mitte und Campus Virchow-Klinikum174
招募中
不适用
Randomized phase II study comparing pegylated interferon alpha-2b combined with intra-arterial 5-fluorouracil and sorafenib alone for advanced hepatocellular carcinomaJPRN-UMIN000008710Iwate Medical University100